ACM
CTSO icon

ACT Capital Management’s Cytosorbents Corp CTSO Stock Holding History

ACT Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$48K Hold
35,000
– – 0.07% 55
2022
Q2 		$77K Hold
35,000
– – 0.11% 55
2022
Q1 		$112K Hold
35,000
– – 0.12% 65
2021
Q4 		$147K Hold
35,000
– – 0.11% 74
2021
Q3 		$284K Hold
35,000
– – 0.15% 72
2021
Q2 		$265K Buy
+35,000
New +$295K 0.14% 80

Other funds holding CTSO

SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACT Capital Management's CTSO Position: Q3 2022 in Review

ACT Capital Management held its Cytosorbents Corp (CTSO) position steady in Q3 2022 at 35,000 shares worth $48K. The position accounts for 0.07% of the portfolio, ranked #55.

ACT Capital Management first reported a position in CTSO in Q2 2021 and has held it in 6 quarters since. The position peaked at $284K in Q3 2021. 60 funds tracked by Wall St. Rank hold CTSO as of Q3 2022.

  • ACT Capital Management held 35,000 shares of Cytosorbents Corp worth $48K as of Q3 2022.
  • ACT Capital Management left its Cytosorbents Corp share count unchanged in Q3 2022.
  • Cytosorbents Corp made up 0.07% of ACT Capital Management's portfolio in Q3 2022, its #55 holding.
  • ACT Capital Management first reported a position in Cytosorbents Corp in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Cytosorbents Corp position peaked at $284K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.